Melatonin: Clinical Perspectives in Neurodegeneration

1Symmetrical losses of neurons in the cognitive, motor, or sensory systems characterize neurodegenerative diseases showing prominent cognitive symptoms, like Alzheimer's disease (AD) and frontotemporal dementia, or predominantly motor symptoms like Parkinson's disease (PD), Huntington's disease or amyotrophic lateral sclerosis. Neuronal death in these entities can be ascribed to interrelated processes like free radical-mediated degeneration, mitochondrial dysfunction, low degree of inflammation and excitotoxicity. Although the regular intake of antioxidants has been proposed for prevention of neurodegeneration, its effectiveness, however, has been questioned. In this context, the cytoprotection given by melatonin use deserves to be considered.

2Melatonin, an unusual phylogenetically conserved compound present in all known aerobic phyla, has a promising significance as a cytoprotective molecule in addition to its chronobiotic properties. The pineal gland is the demonstrable source of melatonin in circulation, the decrease in plasma melatonin being one of the characteristics of advancing age in humans. The focus of this article is on the clinical use of melatonin in neurodegenerative diseases. The discussion of the basic biological data is restricted to its relevance for melatonin doses potentially employable in humans.

3“Chronobiotics” are defined as drugs displaying the capacity to synchronize or to increase the amplitude of the circadian rhythms, melatonin being the prototype. Light-dark variation of melatonin synthesis defines the essential role of melatonin as a chronobiotic. Melatonin “opens the doors of sleep” by inhibiting the propensity to wakefulness derived from the suprachiasmatic nuclei (SCN) in late evening. On the other hand, melatonin is the chemical code of darkness, an information crucial to the neuroendocrine system.

4Although in mammals the circulating melatonin derives almost exclusively from the pineal gland, the methoxyindole is synthesized locally in most cells, tissues, and organs. Indeed, there is now strong evidence that melatonin is produced in every animal cell that has mitochondria, melatonin being involved, among other functions, in the elimination of free radicals and the regulation of immune response to achieve cytoprotection.

5MT1 and MT2 receptors, all belonging to the superfamily of membrane receptors associated with G proteins (G-protein coupled receptors, GPCR) are involved in the chronobiotic action of melatonin. MT1 and MT2 receptors have been identified in the SCN, hippocampus, thalamus, retina, vestibular nuclei and cerebral and cerebellar cortex.

6More recently, another member, GPR50, was included in the melatonin receptor subfamily showing high sequence homology with MT1 and MT2. However, GPR50 does not bind melatonin or any other known ligand. Rather, they form homo- and heteromers between each other and with other GPCRs.

7Melatonin is not only generated and metabolized in the mitochondria but it was recently claimed that the neuroprotective effects of melatonin on the brain injury induced by ischemia/reperfusion were mediated by MT1 receptors located in the mitochondria but not in the membrane. This is remarkable because a GPCR like the MT1 is known as a cell-surface receptor that transmits extracellular signals into the cell.

8Melatonin, an amphiphilic substance, can penetrate cell membranes. In the cytoplasm melatonin interacts with calmodulin and tubulin. Melatonin also enters the cell nucleus where the receptor sites were supposed to belong to the orphan receptor superfamily RZR/ROR. However, RZR/ROR demonstrably does not bind melatonin. Rather, melatonin may act indirectly via this transcription factor, e.g., by affecting the circadian accessory oscillator component RORα through sirtuin-1 (SIRT-1) activation.

9The cytoprotective activity of melatonin exceeds that mediated via receptors. The amounts of melatonin found in almost every cell are much higher than those in circulation. Although the capacity of mitochondria to synthesize melatonin is now confirmed, intracellular melatonin does not get the extracellular space. Indeed, the doses of melatonin needed to change intracellular melatonin concentration are much higher than those employed as a chronobiotic.

10In cell cultures, physiologically relevant effects of melatonin are revealed at doses in the range of 10−8 to 10−9 M, these concentrations being enough for almost complete or total receptor saturation. However, most studies on neuroprotective and anti-inflammatory effects in animals employ pharmacological doses, which clearly exceed the saturation of the receptor.

11The focus in this review is on melatonin effects on neurodegeneration in animal studies as related to the possible human doses to be employed. It must be noted that cell line studies regarding AD and melatonin have delineated important melatonin mediated mechanisms in the line of prevention against AD as well. A comprehensive review on melatonin activity to reverse disrupted signaling mechanisms in neurodegeneration, including proteostasis dysfunction, disruption of autophagic integrity, and anomalies in the insulin, Notch, and Wnt/β-catenin signaling pathways has just been published.

12In a way largely independent of receptors melatonin has antioxidant and scavenging effects. Melatonin has intrinsic free radical scavenging activity as well as is metabolized to compounds that display a higher antioxidant capacity. In addition, melatonin inhibits the synthesis of prooxidant enzymes and facilitates that of antioxidant enzymes. Melatonin exceeds that capacity of vitamin C and E to protect from oxidative damage. Melatonin also exerts cytoprotection in ischemia (independently of free radical scavenging) presumably via mitochondrial membrane stabilization.

13Immunomodulation by melatonin includes proinflammatory and anti-inflammatory effects. The anti-inflammatory actions are of great medical interest since they are found in high-grade inflammation like brain injury, ischemia/reperfusion or sepsis, as well as in low-grade inflammation like aging or neurodegenerative processes.

14The anti-inflammatory properties of melatonin are exerted by inhibiting the binding of nuclear factor κB (NF κB) to DNA (thus decreasing the synthesis of proinflammatory signals), by inhibiting cyclooxygenase (Cox) mainly Cox-2, and by suppressing the expression of the inducible nitric oxide synthase (iNOS). Other signaling pathways involved include prevention of inflammasome NLRP3 activation, upregulation of nuclear factor erythroid 2-related factor 2 and inhibition of toll-like receptor-4 activation and high-mobility group box-1 signaling. The upregulation of SIRT-1 by melatonin appears to be of major importance. Collectively, these effects of melatonin are reflected in reduced levels of proinflammatory cytokines and increased production of anti-inflammatory cytokines.

15The γ-aminobutyric acid (GABA)-ergic system can be involved in the neuroprotection mediated by melatonin. Indeed, melatonin exerts anti-excitatory and sedative effects and information exists that melatonin gives protection to neurons from the toxicity of the amyloid-β (Aβ) peptide via activation of GABAergic receptors. The up-regulation of GABA activity by melatonin could not be blocked by the melatonin receptor antagonist luzindole but it was impaired by the benzodiazepine antagonist flumazenil, suggesting an allosteric modulation of GABAA receptors by melatonin.

16Melatonin displays also anti-excitotoxic activity. For example, melatonin prevents neuronal death induced by kainate, an ionotropic glutamate receptor agonist, and its administration protects hippocampal CA1 neurons from transient anterior ischemia, or from high doses of glucocorticoids. The lack of effects of luzindole or of the MT2 antagonist 4-phenyl-2-propionamidotetralin (4-P-PDOT) excludes the participation of melatonin receptors in melatonin anti-excitotoxic activity.

17In addition to the animal models of AD and PD that are discussed in the present paper, melatonin has been shown to reduce neuronal damage due to the toxicity of cadmium, hyperbaric hyperoxia, toxicity by δ-aminolevulinic acid, γ radiation, focal ischemia, brain trauma, and that resultant from several neurotoxins.

18The extracellular deposits of Aß-formed senile plaques and the intracellular accumulation of neurofibrillary tangles due to hyperphosphorylation of tau protein are the pathological signatures of AD. Aß promotes neuronal degeneration in AD neurons that have become vulnerable to age-related increases of oxidative stress and altered cellular energy metabolism. Hyperphosphorylated tau protein promotes the assembly of microtubules and is an important factor in stabilizing microtubules.

19The 39–43 amino acid residue Aß derives from the amyloid precursor protein (APP). Melatonin interferes with the maturation of APP in several cell lines.

20Table 1 summarizes the effect of melatonin in transgenic models of AD. The data indicate that melatonin modulates APP and Aß metabolism principally at the initial phases of the pathological process. From the doses of melatonin used in these different transgenic models, the human equivalent dose of melatonin for a 75 kg adult can be calculated by normalization of body surface area. Noteworthy, theoretical human equivalent doses calculated from Table 1 results ranged from 2- to 3-orders of magnitude greater than those employed in humans. However, a note of caution must be made since these studies include changes in the expression of genes with mutations characteristic of the hereditary form of AD, only responsible for 5% of AD cases. Senescence-accelerated OXYS rats appears to be a suitable non-transgenic model of sporadic AD (which accounts for 95% of AD patients) as characterized by the progressive age-related aggregation of Aβ and hyperphosphorylation of τ protein as well as mitochondrial dysfunction, loss of synapses, neuronal death, and concomitant cognitive decline. Remarkable, a very low dose of melatonin (0.04 mg daily p.o.) was effective to prevent all these changes. Additional studies are needed to solve the dose incongruences observed.

21How melatonin inhibits generation of Aβ remains undefined. Melatonin may interact with Aß40 and Aß42 inhibiting the formation of progressive β-sheet and/or amyloid fibrils. Such interaction appears to be independent on melatonin antioxidant properties.

22Via blockage of formation of secondary sheets, melatonin may facilitate the peptide clearance induced by proteolytic degradation. Since GSK−3 is a common signaling pathway increasing Aß generation and tau hyperphosphorylation, melatonin could regulate APP and tau processing via protein kinase (PK) C activation and inhibition of GSK-3 pathway. Free radical are involved in Aß-induced neurotoxicity and cell death, melatonin effectively protecting cells against oxidative damage in vitro and in vivo.

23In N2a and SH-SY5Y neuroblastoma cells exposed to wortmannin, calyculin A, or okadaic acid melatonin efficiently attenuated tau hyperphosphorylation via protein kinases and phosphatases, as well as antagonizes the oxidative stress given by these agents. Regulation of PK A, PK C, Ca2+/calmodulin-dependent kinase II, and mitogen-activated protein kinase are other effects of melatonin unrelated to its antioxidant properties.

24A crucial phenomenon for brain homeostasis is waste products' elimination by the glymphatic system. The term “glymphatic” describes active, lymphatic-like, water exchange movements in the brain extracellular space (ECS) driven by perivascular astrocytes, which contain aquaporin-4 (AQP4) located in their end feet. Since the elimination of Aβ peptide is strongly reduced in AQP4−/− mice, occurrence of an AQP4-driven glymphatic Aβ clearance seems feasible.

25During sleep, the elimination of Aβ peptides increases considerably. Thus, the sleep disturbance found as a comorbidity in AD may contribute to the development and progression of the disease via a failure of Aβ clearance. Sleep deprivation disrupted apolipoprotein E clearance from brain ECS. That the glymphatic system participates in tau protein clearance was further indicated by the demonstration that AQP4 deficiency augmented the presence of extracellular tau and neuronal tangle formation in a murine model of traumatic brain injury.

26An important recent observation by Pappolla et al. indicate that the administration of melatonin to AD transgenic mice augments the glymphatic clearance of Aβ. Relevant to this, melatonin is known to preserve slow wave sleep in patients. Indeed, glymphatic dysfunction has been related to various neurological disease in addition to AD, like stroke or traumatic brain injury.

27The rise in the expression of proinflammatory cytokines triggered by microglial activation seems to play a role in the pathogenesis of AD. Microglial release of proinflammatory cytokines induced by NF kB, Aß, and nitric oxide is effectively halted by melatonin. Binding of NF kB to DNA was also inhibited by melatonin.

28Cerebrospinal fluid (CSF) concentration of melatonin decreases even at the preclinical stages of AD. Circulating melatonin correlates negatively with neuropsychological evaluation in mild cognitive impairment (MCI) and AD patients. The relative deficiency of melatonin could be the cause or a consequence of neurodegeneration. In any event, the loss of melatonin aggravates the disease and causes early circadian disturbance as shown by “sundowning”. Sundowning comprises late afternoon or evening symptoms such as agitation, wandering, disorganized thinking, perceptual and emotional disturbances and reductions in attention. Chronotherapeutic interventions, such as timed administration of melatonin and exposure to bright light, relieve sundowning and improved sleep in AD patients.

29The irregular sleep/wake found in AD is effectively treated by melatonin (Table 2). A significant decrease in sundowning and reduced variability of sleep onset time were found in 7 out of 10 dementia patients with sleep disorders treated with 3 mg melatonin at bedtime for 3 weeks.

30In another study including 14 AD patients treated with 6–9 mg/day for a period of 2–3 years, sleep quality improved. Sundowning was no longer detectable except for 2 patients. We also observed improvement of cognitive performance and reduction of amnesia after melatonin treatment. In a case report of monozygotic twins with AD followed for 36 months we reported a better sleep and cognitive function in the twin receiving melatonin.

31The effectiveness of melatonin to improve sleep and alleviate sundowning were reported in open-label and placebo-controlled studies in AD patients. Negative results were also published in fully developed AD patients treated with melatonin. Indeed, large interindividual differences in sleep and agitation are common among AD patients.

32A review of published results on the use of melatonin in AD yielded seven reports (5 open studies, 2 case reports) (N = 89 patients) that supported a possible efficacy of melatonin in improving sleep, decreasing sundowning and improving cognitive deterioration. In six double blind, randomized placebo-controlled trials (N = 210 patients) sleep quality increased, sundowning decreased, and cognitive performance improved in 4 studies (N = 143) whereas there was absence of significant effects in 2 studies (N = 67). Two meta-analyses supported the view that melatonin therapy is effective in improving sleep in patients with dementia. In addition, the melatonergic agent ramelteon was effective in treating delirium of elderly patients in intensive care units.

33Whether melatonin has any value in the treatment of fully developed AD remains undefined. It should be noted that the heterogeneity in pathology of the group examined is probably very high at this stage of disease. Therefore, information obtained at an earlier phase could be more valuable.

34Patients with MCI have a deficit in cognitive functions with preservation of daily activities. MCI is a clinically important stage to identify and treat people at risk because the estimate of the annual rate of conversion of MCI to dementia can be as high as 10–15%, In fact, the degenerative process in the brain of AD begins 20–30 years before the clinical onset of the disease.

35As shown in Table 3, data published from MCI patients consistently showed that melatonin administration improves cognitive performance and sleep quality. For example, we reported a significant improvement of cognitive and depressive symptoms and sleep quality in 35 patients with MCI treated for up to 2 years with 3–9 mg/day of melatonin as an adjuvant. Significantly lower scores in Beck Depression Inventory and better performance in neuropsychological tests and in sleep and wakefulness subjective assessment were documented in 61 outpatients diagnosed with MCI and receiving 3–24 mg of melatonin daily for 15–60 months. Collectively, the results of Table 3 indicate that melatonin is an adjuvant drug useful for the treatment of MCI in a clinical setting.

36The mechanisms that explain the therapeutic effect of melatonin in patients with MCI have not yet been defined. Promotion of slow-wave sleep in the elderly could be beneficial in MCI by increasing the functioning of the glymphatic system, or the secretion of growth hormone and neurotrophins, linked to the restorative phase of sleep.

37The question of whether melatonin has a therapeutic value in the prevention or treatment of MCI deserves further analysis. Multicenter double-blind studies are needed to explore and further investigate the potential and utility of melatonin as a preventive drug against dementia. The doses of melatonin used should be re-evaluated in view of the equivalent human doses of melatonin derived from preclinical data, as indicated in Table 1. Unfortunately, of the 64 clinical trials related to melatonin in an initial state (recruitment and non-recruitment) listed in PubMed (ClinicalTrials.gov Search results 01/03/2019) none is directed to this query.

38The progressive degeneration of neurons containing dopamine (DA) in the substantia nigra pars compacta (SNpc) characterizes PD. Since Lewy bodies are found not only in DA neurons but also in noradrenergic neurons of the brainstem, in serotonergic neurons of the raphe nuclei and in specific cholinergic neurons, PD is seen as a progressive disease affecting a variety of neurotransmitter systems. This explains the number of non-motor symptoms in PD, such as genitourinary, gastrointestinal, respiratory and cardiovascular disorders, anosmia and neuropsychiatric, visual, and sleep-related disorders. In fact, the non-motor preclinical phase of PD can cover more than 20 years, the relevance of neuroprotection being evident in this respect.

39The inflammatory signature found in the pathogenesis of PD includes microglial activation, astrogliosis and lymphocytic infiltration. Several inflammatory mediators, e.g., NF-κB, interleukin (IL)-1, IL-6, Cox-2, tumor necrosis factor-α, iNOS, and interferon-γ are produced by glial cells.

40PD and other Lewy body diseases are characterized by the aggregation of fibrillar α-synuclein. Mitochondrial dysfunction plays a role in this process since the folding and aggregation of proteins are promoted by free radicals.

41To develop animal models of altered brain DA function, 6-hydroxydopamine (6-OHDA), or the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), were injected into the nigrostriatal pathway of the rat.

42Because of its potentiality to cause the disease in humans and in subhuman primates, MPTP is preferred among other neurotoxins to emulate parkinsonism in animal models. MPTP is selectively taken up by astrocytes and is metabolized into methyl 1-4 phenyl pyridinium (MPP+), this cation causing increased production of free radicals, depletion of ATP, and apoptosis. MPTP toxicity is selective to SNpc neurons and induced loss of striatal spines in non-human primates. Such striatal spine loss is a consistent neuropathologic finding in post-mortem PD human brains. Although the MPTP-treated monkey is considered the best experimental model of PD, a major drawback is the consistent lack of other neuronal loss besides the nigrostriatal dopaminergic system.

43In Table 4 the in vivo effects of melatonin in several experimental models of PD are shown. Most experiments support the role of melatonin in prevention and treatment of experimental PD. As in the case of Table 1, the human equivalent doses of melatonin for a 75 kg adult, calculated by normalization of body surface area, are quoted for the sake of comparison with those employed in PD patients. Again, theoretical human equivalent doses derived from animal data are considerably greater than those employed in humans.

44Most of the studies summarized in Table 4 include pretreatment with the methoxyindole and therefore they rely on the neuroprotective effect of melatonin preventing the death of dopaminergic neurons and consequently motor dysfunction (Table 4). In addition, some studies failed to observe motor benefits of melatonin treatment in animal models of PD regardless of protection of neurodegeneration. For example, Bassani et al. reported that the melatonin post-treatment for 28 days preserved tyrosine hydroxylase positive neurons and DA levels of rotenone-lesioned rats and improved the depressive-like behavior in the absence of significant improvement of motor deficit.

45In PD patients, administration of 3 mg of melatonin for 4 weeks improved the quality of sleep but did not affect motor symptoms. Moreover, by evaluating the effects of slow release melatonin preparation via intracerebroventricular implants in rats injected with 6-OHDA or MPTP, Willis and Armstrong reported that melatonin indeed deteriorated motor performance. Remarkably, other studies reported an enhancement of motor deficit in animal models of PD after the administration of the antagonist of melatonin receptors ML-23. The beneficial effect of melatonin antagonism on motor symptoms of PD could be explained by inhibition of DA release by the methoxyindole.

46Regardless of these discrepancies, melatonin preventing activity on PD-related neurodegeneration is generally accepted. For example, melatonin inhibits α-synuclein assembly and attenuated kainic acid-induced neurotoxicity and arsenite-induced apoptosis. Melatonin also impaired the augmented expression of α-synuclein in DA containing neurons following amphetamine administration. Melatonin blocked α-synuclein fibril formation and destabilized preformed fibrils by inhibiting protofibril formation and secondary structure transitions and by reducing α-synuclein cytotoxicity.

47An insufficient clearance by the autophagic–lysosomal network can explain the accumulation and spread of oligomeric forms of neurotoxic α-synuclein. In addition, other clearance pathways are compromised, like the ubiquitin–proteasome system, the autophagy mediated by chaperone, extracellular clearance by proteases, or entrance into the general circulation via the glymphatic system.

48As above mentioned, the elimination of waste products by the glymphatic system considerably contributes to recovery processes in the brain. The role of AQ4 water channels in the glymphatic system seems to be crucial and, remarkably, AQ4 expression is severely disrupted in PD brains. It may explain why the CSF α-synuclein levels inversely correlate with symptoms in PD patients. The association of loss of sleep with impairment of the glymphatic clearance is important in the case of PD because rapid eye movement sleep behavior disorder (RBD) is a prodrome of PD. Melatonin administration to animals augments glymphatic clearance as well as preserved sleep in patients. Curiously, melatonin was not listed in the myriad of drugs affecting anomalous protein clearance in the brain.

49Symptomatically, an effective treatment for PD is the supplementation of DA in its precursor form L-dihydroxyphenylalanine (L-DOPA) that crosses the blood brain barrier. However, long-term administration of -L-DOPA leads to motor side effects like dyskinesias. Moreover, administration of L-DOPA in high doses leads to production of neurotoxic molecules like 6-OHDA. Therefore, efforts to reduce the intake or to compensate for the side effects of L-DOPA are in the vogue. In MPTP-treated mice, melatonin, but not L-DOPA, restored striatal spine density, supporting the application of melatonin as an adjuvant to L-DOPA therapy in PD.

50Approximately 3/4 of the dopaminergic cells in the SNpc need to be lost to uncover motor symptomatology in PD. However, non-motor symptoms like hyposmia, depression, or RBD (characterized by the occurrence of vivid, intense, and violent movements during REM sleep) precede the onset of PD for years and are index of worse prognosis. Indeed, up to 65% of patients showing RBD developed PD 10–13 years later.

51Table 5 summarizes the clinical studies reporting melatonin use in PD. Daily administration of 3–12 mg of melatonin at bedtime is effective in the treatment of RBD. Polysomnography (PSG) in RBD patients treated with melatonin showed significant decreases in number of R epochs without atonia and in movement time during REM sleep, contrasting with the persistence of muscle tone in R sleep seen with patients treated with clonazepam. Based on these data, a clinical consensus recommended melatonin use in RBD at Level B.

52Another consensus has claimed for trials with neuroprotective agents in RBD based on the high conversion rate from idiopathic RBD to PD. Indeed, the conversion rate to synucleinopathy in clonazepam-treated RBD patients is high. Although no comparable data are available yet for melatonin-treated RBD patients, a recent observation by Kunz and Bes deserves to be considered. The investigators reported the increase in DA transporter density (as assessed by DA transporter scintigraphy) over successive years in a 72-year-old RBD male patient treated with 2 mg of slow release melatonin daily. After 6 months of gradual improvement, clinical and PSG signs of RBD disappeared. Whereas, the scan prior to melatonin treatment had clear signs of PD, the scan recorded 2 years later was considered borderline, with absence of any sign of PD 4 years after the first scan. The results were interpreted as a possible neuroprotective role for melatonin in synucleinopathy.

53A phase advance in nocturnal melatonin secretion was reported in L-DOPA-treated parkinsonian patients. L-DOPA-treated patients exhibited an increase in daytime melatonin secretion perhaps as an adaptive response to neurodegeneration. In a study aiming to examine circadian dysfunction as a cause for excessive sleepiness in PD, blunted circadian rhythms of melatonin were reported. The amplitude of the melatonin rhythm decreased in PD patients, mainly in those depicting excessive daytime sleepiness. Thus, a chronobiological approach to improve circadian function, such as timed exposure to melatonin and bright light, could serve as an adjuvant therapy for the non-motor manifestations of PD.

54An association between motor fluctuations in PD and diurnal variation in circulating melatonin levels was postulated via possible interactions of melatonin with monoamines (DA, serotonin) in the striatal complex. Nearly half of the patients with PD showed L-DOPA-related motor complications after 5 years of treatment. In view of the results obtained in experimental parkinsonism discussed above, the use of melatonin as an adjuvant to decrease the therapeutic dosage of L-DOPA in PD deserves to be considered.

55Wearing-off episodes in PD could be related to loss of the inhibitory motor effect of melatonin, since stimulation of globus pallidus improved motor symptoms and complications in patients with PD as well as inhibited the increase in daytime plasma melatonin levels found. Relevant to the subject of the present review, genetic susceptibility and life-style factors (e.g., smoking) have been entertained to explain the epidemiological that longer years of working night shifts are associated with reduced risk of PD and decreased melatonin levels.

56Patients with PD showed decreased melatonin MT1 and MT2 receptor density in amygdala and substantia nigra. Supporting that a disrupted melatonergic system could be involved in the altered sleep/wake cycle seen in PD, an actigraphic study undertaken in 40 PD patients indicated that melatonin (50 mg/day at bedtime) increased nighttime sleep. Those patients taking 5 mg of melatonin only reported a significant improvement of subjectively evaluated sleep.

57In another study, 18 PD patients were randomized after performing a basal PSG to receive melatonin (3 mg) or placebo 1 h before bedtime for 4 weeks. Although melatonin significantly improved the subjective quality of sleep, the motor dysfunction was not improved.

58An important experimental study carried out in the MPTP monkey model of PD evaluated the effects of melatonin and L-DOPA on sleep disorders as monitored by PSG. The combined treatment of melatonin and L-DOPA significantly curtailed sleep fragmentation at night and sleep episodes during the day seen in MPTP-treated monkeys, thus indicating that melatonin treatment may have the therapeutic potential to treat sleep disorder in PD patients.

59Exposure to 1–1.5 h of light (1,000–1,500 lux) prior to bedtime reduced bradykinesia and rigidity in PD patients, as well as agitation and psychiatric side effects. The authors concluded that suppressing melatonin secretion with bright light may have a therapeutic value for treating the symptoms of PD. However, suppression of melatonin secretion may not be the likely mechanism by which artificial light exerts its therapeutic effect, as shown in depressive patients subjected to phototherapy. In any event, the circadian system is considered a novel diagnostic and therapeutic target in PD.

60Figure 1 summarizes that different mechanisms by which melatonin may halt AD and PD progression. Depicted intersections in the Figure represent the multiple effects of melatonin and the different degree of overlap (interrelations and mutual influences) discussed in the text.

61Because of both hypnotic and chronobiotic properties, the use of melatonin has been recommended for treatment of insomnia. Several meta-analyses support such therapeutic role. A consensus of the British Association for Psychopharmacology on evidence-based treatment of insomnia concluded that melatonin is the first choice treatment when a hypnotic is indicated in patients over 55 years.

62As discussed in this article, studies using 2–5 mg melatonin/day are unsuitable to give appropriate comparison with data on neurodegeneration protection derived from animal studies. Melatonin is remarkably atoxic and its safety is very high. Lethal dose 50 (LD50) for intraperitoneal melatonin injection was 1,131 mg/kg for mice and 1,168 mg/kg for rats. However, LD50 could not be constructed after oral administration of up to 3,200 mg of melatonin/kg in rats, or after subcutaneous injection of up to 1,600 mg/kg in rats and mice. In humans, melatonin has a high safety profile and it is usually remarkably well-tolerated (Table 6). Presently, the only option for the incumbent physician interested in the use of melatonin as a cytoprotective is the off-label indication of the drug.

63Off-label drugs are defined as drug uses that not included in the indications or dosage regimens listed by the administrative body that registers, controls, and monitors medicines authorized, e.g., the Food and Drug Administration in USA. Off label drug use is common in intensive care unit, pediatrics, psychiatry and oncology. In general, no law prohibits off-label drug use and prescribing off-label is legally accepted in most legislations.

64In Argentina, the National Administration for Medicaments, Food and Medical Technology (ANMAT) approved melatonin (3 mg capsules or tablets) as an over-the-counter medication in 1995. In 2017 ANMAT authorized a prolonged release preparation of 2 mg melatonin (CircadinR) as a prescription drug. Although ANMAT cannot authorize the use of a medication for an indication not listed in the package leaflet, it does not mean that the indication of a medication for other clinical situations is prohibited. In accordance to ANMAT, The off-label prescriptions are “the sole responsibility of the attending physician, who performs them in the full exercise of their professional activity, based on their experience and the available scientific knowledge, motivated by the need to provide an answer to health problems for which there are no standards of treatment or that, in case of existing, they are very difficult to access.”

65In many countries, melatonin is used as a food supplement or dietetic products. Indeed, the European Food Safety Authority (EFSA) has endorsed the health claim that melatonin reduces sleep onset latency. Thus, melatonin, melatonin-rich food and bioextracts could now be developed.

66Overexpression of melatonin in plants facilitates the germination of seeds and protects plants from abiotic and biotic stress and potentially genetically manipulated plants may have use in human nutrition. In parallel, toxicity of long-term melatonin use must be evaluated.

67In conclusion, from animal studies several potentially useful effects of melatonin, like those in neurodegenerative disorders, need high doses of melatonin to become apparent. Regardless of the amount of experimental data gathered as far as how melatonin acts in animal and cell models, in most cases it is not known whether it works as a chronobiotic drug, as an endogenous antioxidant or as an immunomodulatory compound. This is an important caveat deserving consideration.

68Although melatonin is remarkably atoxic and its safety is very high in adults, caution must be exerted with melatonin use in children taking in consideration that melatonin is known to inhibit LH secretion from neonatal pituitary gonadotrophs in the rat. Even if similar effect has not yet been documented in human, it cannot be excluded that treatment with high doses of exogenous melatonin could influence the development of the reproductive system.

69The author confirms being the sole contributor of this work and has approved it for publication.

70The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.